What symptoms may indicate hepatotoxicity in a patient on INH?

The correct response identifies several key signs and symptoms that could indicate hepatotoxicity in a patient receiving isoniazid (INH), a medication commonly used to treat and prevent tuberculosis. Hepatotoxicity refers to liver damage caused by chemicals, and INH is known for its potential to cause liver toxicity, especially when used over prolonged periods or in patients with preexisting liver conditions.

Jaundice, which is characterized by a yellowing of the skin and the whites of the eyes, occurs due to the buildup of bilirubin in the bloodstream and is a classic sign of liver dysfunction. Dark urine can also occur as a result of bilirubin being excreted through the urine when the liver is not functioning properly. Fatigue is often linked to liver issues, as the liver plays a critical role in metabolism and energy production. Additionally, abdominal pain, particularly in the upper right quadrant, can signify liver distress or inflammation.

Each of these symptoms is directly related to liver function and can help healthcare providers identify potential hepatotoxicity early, enabling timely intervention to prevent severe complications. Other symptoms related to the other options may indicate different medical conditions but are not specific indicators of liver damage associated with INH therapy.